, MARCH 18,
2011
ROCHESTER, N.Y. -- Bausch + Lomb, the global eye health company,
today announced the appointment of Calvin W. Roberts, M.D. to the
newly created position of Chief Medical Officer (CMO). Dr. Roberts
will serve as a member of the Executive Leadership Team and
coordinate the company’s global D&R efforts across the
Vision Care, Pharmaceuticals and Surgical business units for
greater leverage and outcomes.
Dr. Roberts brings a unique combination of academic, clinical
and product development experience to the new Bausch + Lomb CMO
role. A specialist in cataract and refractive surgery, Dr. Roberts
is credited with developing and producing over-the-counter products
for vision care, prescription ocular therapeutics and innovative
treatment regimens. Dr. Roberts is considered to be the
“father” of ophthalmic non-steroidals; he has published
50 peer-reviewed articles.
“We are extremely pleased with the addition of Dr. Calvin
Roberts to the Bausch + Lomb leadership team in this critical new
role as chief medical officer,” said Brent Saunders, chief
executive officer of Bausch + Lomb. “As a renowned expert in
ophthalmology and the development of eye health products, Cal is
uniquely qualified to help us further strengthen product
innovation, benefiting our customers and their patients around the
world.”
Dr. Roberts is a member of the board of directors at Alimera
Sciences, a biopharmaceutical company he co-founded in 2003. Dr.
Roberts is a clinical professor of ophthalmology at Weill Medical
College of Cornell University. Dr. Roberts holds patents on the
wide-field specular microscope, used for corneal endothelial
studies, and is the developer of instruments for cataract surgery.
As a consultant to ophthalmic pharmaceutical companies, including
Allergan Pharmaceuticals, Johnson & Johnson and Novartis, Dr.
Roberts has helped lead the development and marketing efforts for
several new therapeutics.
A graduate of Princeton University and the College of Physicians
and Surgeons of Columbia University, Dr. Roberts completed his
internship and ophthalmology residency at Columbia Presbyterian
Hospital in New York. Dr. Roberts also completed cornea fellowships
at Massachusetts Eye and Ear Infirmary and the Schepens Eye
Research Institute in Boston.
“I look forward to bringing the perspective of clinical
optometrists and ophthalmologists to the development of new,
innovative products to benefit our patients,” said Dr. Calvin
Roberts. “Bausch + Lomb has a history of great science and
great scientists, and working together we can best serve the needs
of our customers and patients.”
SOURCE